Ind-Swift Laboratories Ltd
Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]
- Market Cap ₹ 732 Cr.
- Current Price ₹ 99.6
- High / Low ₹ 160 / 67.2
- Stock P/E 33.5
- Book Value ₹ 192
- Dividend Yield 0.00 %
- ROCE 4.11 %
- ROE 4.12 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.52 times its book value
- Company is expected to give good quarter
- Company has delivered good profit growth of 32.3% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -3.22%
- The company has delivered a poor sales growth of -6.07% over past five years.
- Company has a low return on equity of 9.48% over last 3 years.
- Contingent liabilities of Rs.465 Cr.
- Earnings include an other income of Rs.264 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
941 | 646 | 639 | 694 | 731 | 724 | 752 | 857 | 988 | 1,152 | 1,673 | 550 | 417 | |
882 | 557 | 532 | 589 | 604 | 599 | 610 | 676 | 788 | 930 | 1,374 | 563 | 440 | |
Operating Profit | 59 | 89 | 107 | 105 | 127 | 125 | 142 | 180 | 200 | 222 | 299 | -13 | -23 |
OPM % | 6% | 14% | 17% | 15% | 17% | 17% | 19% | 21% | 20% | 19% | 18% | -2% | -6% |
-19 | -31 | 1 | 15 | 16 | 130 | 36 | 23 | 34 | 7 | 479 | 304 | 264 | |
Interest | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 51 | 3 | -15 |
Depreciation | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 53 | 24 | 20 |
Profit before tax | -143 | -143 | -83 | -56 | 29 | 59 | -20 | 16 | 8 | 79 | 577 | 264 | 235 |
Tax % | -14% | -17% | -29% | -29% | 38% | 35% | 6% | 127% | 171% | 46% | 28% | 3% | |
-123 | -119 | -59 | -40 | 18 | 39 | -21 | -4 | -6 | 42 | 418 | 256 | 226 | |
EPS in Rs | -29.96 | -29.09 | -14.37 | -8.88 | 3.89 | 8.11 | -3.52 | -0.74 | -0.97 | 7.19 | 70.81 | 42.25 | 37.22 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -2% |
5 Years: | -6% |
3 Years: | -18% |
TTM: | -62% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 32% |
3 Years: | 165% |
TTM: | -89% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 21% |
3 Years: | 18% |
1 Year: | -25% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 6% |
3 Years: | 9% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 59 | 69 |
Reserves | 682 | 551 | 473 | 480 | 497 | 542 | 585 | 579 | 573 | 616 | 863 | 1,095 |
1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 996 | 944 | 854 | 8 | 37 | |
252 | 233 | 238 | 353 | 371 | 174 | 184 | 182 | 226 | 259 | 174 | 221 | |
Total Liabilities | 2,330 | 2,238 | 2,210 | 2,121 | 1,997 | 1,913 | 1,860 | 1,817 | 1,803 | 1,788 | 1,105 | 1,422 |
1,173 | 1,114 | 1,095 | 1,042 | 934 | 913 | 843 | 752 | 630 | 587 | 8 | 273 | |
CWIP | 78 | 115 | 82 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 0 | 0 |
Investments | 27 | 26 | 26 | 26 | 26 | 26 | 26 | 55 | 111 | 85 | 166 | 269 |
1,052 | 983 | 1,007 | 982 | 968 | 953 | 979 | 991 | 1,052 | 1,108 | 931 | 880 | |
Total Assets | 2,330 | 2,238 | 2,210 | 2,121 | 1,997 | 1,913 | 1,860 | 1,817 | 1,803 | 1,788 | 1,105 | 1,422 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 100 | 80 | 93 | 71 | -75 | 123 | 135 | 136 | 183 | -180 | -39 | |
0 | -37 | -30 | -31 | -17 | -2 | -10 | -10 | 3 | -14 | -104 | -110 | |
0 | -64 | -48 | -69 | -62 | 100 | -133 | -124 | -140 | -168 | 700 | 74 | |
Net Cash Flow | 0 | -0 | 3 | -7 | -8 | 23 | -20 | 1 | -1 | 1 | 416 | -75 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 166 | 212 | 205 | 179 | 191 | 168 | 187 | 171 | 158 | 149 | 23 | 106 |
Inventory Days | 187 | 319 | 377 | 317 | 305 | 302 | 330 | 304 | 303 | 253 | 0 | 137 |
Days Payable | 102 | 119 | 137 | 88 | 112 | 110 | 122 | 106 | 120 | 114 | 141 | |
Cash Conversion Cycle | 250 | 412 | 445 | 409 | 384 | 359 | 395 | 368 | 342 | 287 | 23 | 102 |
Working Capital Days | 128 | 32 | -35 | -106 | -59 | 225 | 256 | 243 | 249 | 226 | -13 | 109 |
ROCE % | 0% | 1% | 2% | 2% | 3% | 4% | 5% | 7% | 7% | 13% | 25% | 4% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 Aug - Monitoring report confirms Rs.314.6 Cr preferential issue funds used as per objectives, no deviations.
- Standalone And Consolidated Un-Audited Financial Results Of Ind-Swift Laboratories Limited For The Quarter Ended 30Th June, 2025 13 Aug
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 13TH AUGUST, 2025
13 Aug - Ind-Swift Labs Q1 FY26 unaudited standalone and consolidated financial results approved and published.
-
Board Meeting Outcome for Outcome Of Board Meeting Dated August 11, 2025
11 Aug - Audited FY25 financial results approved; amalgamation with Ind-Swift Limited effective; preference shares allotted and redeemed.
- Results-Delay in Financial Results 11 Aug
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ISLL is a global manufacture of APIs, Intermediates and formulation (through group collaboration). It caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. ISLL is present in all stages of drug substance/product including new chemical/molecular research to formulation development.
Company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. It also holds global leadership positions in the Macrolide Antibiotic segment.